zatolmilast (BPN14770) / Shionogi  >>  Phase 1
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
zatolmilast (BPN14770) / Shionogi
NCT02648672: BPN14770 Single Ascending Dose Study in Healthy Male and Female Subjects

Completed
1
32
US
BPN14770, Placebo
Tetra Discovery Partners
Alzheimer's Disease
02/16
07/16
NCT02840279: A Multiple Ascending Dose Study of BPN14770 in Healthy Young and Elderly Male or Female Subjects

Completed
1
77
US
BPN14770, Placebo
Tetra Discovery Partners
Alzheimer's Disease
11/16
12/16
NCT03030105: Study to Evaluate the Effects of BPN14770 on Scopolamine-induced Cognitive Impairment in Healthy Volunteers

Completed
1
38
US
BPN14770, BPN14770 placebo, Donepezil, Aricept, Donepezil placebo, Aricept placebo, Scopolamine 0.6 MG/ML, Hyoscine s.c., Scopolamine placebo, Hyoscine s.c. placebo
Tetra Discovery Partners
Alzheimer Disease
05/17
06/17
NCT04044781: A Phase 1, Open-Label, PET Study of T2310 & BPN14770

Withdrawn
1
0
US
BPN14770, T2310
Tetra Discovery Partners
To Determine Brain Target Occupancy of BPN14770
04/20
05/20

Download Options